Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors

Advances in Therapy

Volumn 27, Issue 8, 2010, Pages 495-511

  Chan, Hiu Yan ^a   Grossman, Ashley B ^a   Bukowski, Ronald M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

endocrine tumors; everolimus; gastroenteropancreatic; islet cell carcinoma; kidney cancer; mTOR inhibitor; neuroendocrine tumors; RAD001; rapamycin; renal cell carcinoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA INTERFERON; CHOLESTEROL; CHROMOGRANIN A; DACARBAZINE; EVEROLIMUS; GLUCOSE; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN; NEURON SPECIFIC ENOLASE; OCTREOTIDE; PAZOPANIB; PLACEBO; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APHTHOUS ULCER; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FATIGUE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOPHOSPHATEMIA; INFECTION; INSULINOMA; ISOTOPE LABELING; KIDNEY CARCINOMA; LABORATORY TEST; LIVER FUNCTION TEST; LUNG METASTASIS; LYMPHOCYTE; MONOTHERAPY; NAUSEA; NEPHRECTOMY; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RADIOISOTOPE THERAPY; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; OCTREOTIDE; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77956230880     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0045-2     Document Type: Review

References (51)

1. S.N. Sehgal H. Baker C. Vézina 1975 Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization J Antibiot (Tokyo) 28 727 732
2. J. Douros M. Suffness 1981 New antitumor substances of natural origin Cancer Treat Rev. 8 63 87 10.1016/S0305-7372(81)80006-0 7248995
3. S. Grozinsky-Glasberg G. Franchi M. Teng 2008 Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuroendocrine tumour cell Line Neuroendocrinology 87 168 181 10.1159/000111501 18025810
4. J.A. Chan M.H. Kulke 2009 Progress in the treatment of neuroendocrine tumors Curr Oncol Rep. 11 193 199 10.1007/s11912-009-0028-0 19336011
5. S. Vignot S. Faivre D. Aguirre E. Raymond 2005 mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol. 16 525 537 10.1093/annonc/mdi113 15728109
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. V.2.2010. Available at: www.nccn.org. Accessed January 24, 2010.
7. C. Coppin F. Porzsolt M. Autenrieth J. Kumpf A. Coldman T. Wilt 2004 Immunotherapy for advanced renal cell cancer Cochrane Database Syst Rev. 3 CD001425
8. R.J. Motzer T.E. Hutson P. Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med. 356 115 124 10.1056/NEJMoa065044 17215529
9. R.J. Motzer T.E. Hutson P. Tomczak 2009 Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol. 27 3584 3590 10.1200/JCO.2008.20.1293 19487381
10. B. Escudier T. Eisen W.M. Stadler 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med. 356 125 134 10.1056/NEJMoa060655 17215530
11. T.E. Hutson I.D. Davis J.P. Machiels 2010 Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma J Clin Oncol. 28 475 480 10.1200/JCO.2008.21.6994 20008644
12. B. Escudier A. Pluzanska P. Koralewski 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031
13. G. Hudes M. Carducci P. Tomczak 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med. 356 2271 2281 10.1056/NEJMoa066838 17538086
14. R.J. Motzer B. Escudier S. Oudard 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 10.1016/S0140-6736(08)61039-9 18653228
15. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. Published online June 14, 2010.
16. B. Escudier T. Eisen W.M. Stadler 2009 Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol. 27 3312 3318 10.1200/JCO.2008.19.5511 19451442
17. D. Wiederkehr C.J. Howe R. Casciano 2009 Overall survival among metastatic renal cell carcinoma patients corrected for crossover using inverse probability of censoring weights: analyses from the RECORD-1 phase 3 trial Eur J Cancer Suppl. 7 432 10.1016/S1359-6349(09)71464-8
18. P.H. Patel R.S. Chadalavada R.S. Chaganti R.J. Motzer 2006 Targeting von Hippel-Lindau pathway in renal cell carcinoma Clin Cancer Res. 12 7215 7220 10.1158/1078-0432.CCR-06-2254 17189392
19. J. Brugarolas 2007 Renal-cell carcinoma - molecular pathways and therapies N Engl J Med. 356 185 187 10.1056/NEJMe068263 17215538
20. A.J. Pantuck D.B. Seligson T. Klatte 2007 Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy Cancer 109 2257 2267 10.1002/cncr.22677 17440983
21. V.A. Robb M. Karbowniczek A.J. Klein-Szanto E.P. Henske 2007 Activation of the mTOR signaling pathway in renal clear cell carcinoma J Urol. 177 346 352 10.1016/j.juro.2006.08.076 17162089
22. E. Juengel J. Engler I. Natsheh 2009 Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells BMC Cancer 9 161 10.1186/1471-2407-9-161 19473483
23. R.J. Amato J. Jac S. Giessinger S. Saxena J.P. Willis 2009 A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer Cancer 115 2438 2446 10.1002/cncr.24280 19306412
24. Porta C, Ravaud A, Osanto S, et al. Recommendations for adverse event management in patients with renal cell carcinoma treated with everolimus: safety data from the RECORD-1 trial. Poster presented at the 8th International Kidney Cancer Symposium, September 25-26, 2009, Chicago, IL, USA.
25. EAU. Guidelines on Renal Cell Carcinoma. European Association of Urology 2010. Available at: www.uroweb.org. Accessed June 14, 2010.
26. B. Escudier V. Kataja 2009 ESMO Guidelines Working Group. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol. 20 Suppl4 81 82 19454473
27. T.M. de Reijke J. Bellmunt H. van Poppel S. Marreaud M. Aapro 2009 EORTC-GU group expert opinion on metastatic renal cell cancer Eur J Cancer 45 765 773 10.1016/j.ejca.2008.12.010 19157861
28. P.A. Jänne N. Gray J. Settleman 2009 Factors underlying sensitivity of cancers to small-molecule kinase inhibitors Nat Rev Drug Discov. 8 709 23 10.1038/nrd2871 19629074
29. Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. J Urol. 2010; March 9 [Epub ahead of print]
30. M.P. Sablin S. Negrier A. Ravaud 2009 Sequential sorafenib and sunitinib for renal cell carcinoma J Urol. 182 29 34 10.1016/j.juro.2009.02.119 19447417
31. A.Z. Dudek J. Zolnierek A. Dham B.R. Lindgren C. Szczylik 2009 Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 61 67 10.1002/cncr.24009 19051290
32. G. Di Lorenzo G. Cartenì R. Autorino 2009 Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer J Clin Oncol. 27 4469 4474 10.1200/JCO.2009.22.6480 19652053
33. D.R. Shepard B.I. Rini J.A. Garcia 2008 A multicenter prospective trial of sorafenib in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab J Clin Oncol. 26 5123
34. J.C. Yao M. Hassan A. Phan 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol. 26 3063 3072 10.1200/JCO.2007.15.4377 18565894
35. A. Rinke H.H. Müller C. Schade-Brittinger 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol. 27 4656 4663 10.1200/JCO.2009.22.8510 19704057
36. G. Capurso N. Fazio S. Festa 2009 Molecular target therapy for gastroenteropancreatic endocrine tumours: biological rationale and clinical perspectives Crit Rev Oncol Hematol. 72 110 124 10.1016/j.critrevonc.2009.01.008 19249226
37. E. Missiaglia I. Dalai S. Barbi 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol. 28 245 255 10.1200/JCO.2008.21.5988 19917848
38. J.C. Yao 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma Best Pract Res Clin Endocrinol Metab. 21 163 172 10.1016/j.beem.2007.01.006 17382271
39. D. Dworakowska A.B. Grossman 2009 Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review Endocr Relat Cancer 16 45 58 10.1677/ERC-08-0142 18978035
40. K. Zitzmann E.N. De Toni S. Brand 2007 The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells Neuroendocrinology 85 54 60 10.1159/000100057 17310129
41. V. Cerovac J. Monteserin-Garcia H. Rubinfeld 2010 The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells Cancer Res. 70 666 674 10.1158/0008-5472.CAN-09-2951 20068168
42. S. Grozinsky-Glasberg H. Rubinfeld Y. Nordenberg 2010 The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells Mol Cell Endocrinol. 315 87 94 10.1016/j.mce.2009.09.027 19815051
43. D. Hörsch S. Tielke J. Schrader 2007 Expression and activation of mTOR in neuroendocrine tumors. Effects of mTOR inhibition by RAD001 upon growth, cell cycle regulation and signalling in neuroendocrine cell lines J Clin Oncol. 25 18S 582s
44. L. Righi M. Volante V. Tavaglione 2008 Mammalian target of rapamycin (MTOR) signaling activation patterns in neuroendocrine tumors of the lung Virchows Arch. 452 Suppl1 S15
45. J.C. Yao A.T. Phan D.Z. Chang 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study J Clin Oncol. 26 4311 4318 10.1200/JCO.2008.16.7858 18779618
46. J.C. Yao C. Lombard-Bohas E. Baudin 2010 Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial J Clin Oncol. 28 69 76 10.1200/JCO.2009.24.2669 19933912
47. M.H. Kulke E.K. Bergsland J.C. Yao 2009 Glycemic control in patients with insulinoma treated with everolimus N Engl J Med. 360 195 197 10.1056/NEJMc0806740 19129539
48. M.E. Bourcier A. Sherrod M. DiGuardo A.I. Vinik 2009 Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases J Clin Endocrinol Metab. 94 3157 3162 10.1210/jc.2009-0788 19567519
49. I.B. Leibiger B. Leibiger T. Moede P.O. Berggren 1998 Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways Mol Cell. 1 933 938 10.1016/S1097-2765(00)80093-3 9660977
50. D.K. Fuhrer M. Kobayashi H. Jiang 2001 Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel Diabetes Obes Metab. 3 393 402 10.1046/j.1463-1326.2001.00150.x 11903410
51. M.R. Druce G.A. Kaltsas M. Fraenkel D.J. Gross A.B. Grossman 2009 Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) Horm Metab Res. 41 697 702 10.1055/s-0029-1220687 19424940